	US 12,458,818 B2
	Anti-trophoblast cell surface antigen 2 (TROP2) antibodies and antibody drug conjugates comprising same
Yuxi Shan, Sacramento, CA (US); Lixin Feng, Sacramento, CA (US); Ryan Joseph Browde, Sacramento, CA (US); Lisha Allen, Sacramento, CA (US); and Ru Bin Yang, Sacramento, CA (US)
Assigned to CSPC MEGALITH BIOPHARMACEUTICAL CO., LTD., Hebei (CN)
Appl. No. 17/437,423
Filed by CSPC MEGALITH BIOPHARMACEUTICAL CO., LTD., Hebei (CN)
PCT Filed Mar. 18, 2020, PCT No. PCT/US2020/023421 § 371(c)(1), (2) Date Sep. 9, 2021, PCT Pub. No. WO2020/191092, PCT Pub. Date Sep. 24, 2020.
Claims priority of provisional application 62/820,831, filed on Mar. 19, 2019.
Prior Publication US 2022/0153862 A1, May 19, 2022
Int. Cl. A61P 35/00 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01)

CPC A61K 47/6851 (2017.08) [A61K 47/68031 (2023.08); A61P 35/00 (2018.01); C07K 16/30 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)]

25 Claims

1. An anti-Trophoblast cell surface antigen 2 (TROP2) antibody or antigen-binding fragment thereof that specifically binds TROP2, comprising:

i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:39; iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 10; iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 14; v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 17; and vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 19;

or, comprising: i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5; iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 10; iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 14; v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 17; and vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 19.